Related Experiment Videos
Familial ovarian cancer
R E Buller1, B Anderson, J P Connor
1Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City 52242.
Gynecologic Oncology
|November 1, 1993
Summary
Familial ovarian cancer cases show significantly better survival rates than non-familial cases. Germline p53 mutations were identified in some families, suggesting a role in hereditary ovarian cancer development.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Familial cancer clusters offer insights into malignancy development.
- Epithelial ovarian cancer (EOC) exhibits varied clinical courses.
- Distinguishing familial from non-familial EOC is crucial for understanding disease mechanisms.
Purpose of the Study:
- To investigate the molecular underpinnings of familial ovarian cancer.
- To compare the clinical characteristics and survival outcomes of familial versus non-familial ovarian cancer.
- To identify potential genetic factors, such as p53 mutations, associated with hereditary ovarian cancer.
Main Methods:
- Identified 11 members across four families with epithelial ovarian cancer.
- Selected 34 matched non-familial ovarian cancer cases for comparison (age, histology, stage, grade).
- Analyzed HER-2/neu oncogene expression and p53 tumor suppressor gene status (germline and tumor).
Main Results:
- Familial ovarian cancer patients had a 67% 5-year survival rate, compared to 17% in non-familial cases.
- HER-2/neu oncogene overexpression was not observed in familial cancer tumors.
- Abnormal p53 expression was found in 4/6 tested familial cancers, with germline p53 mutations in 3/4 families.
Conclusions:
- Familial ovarian cancer demonstrates a more indolent clinical course and improved survival.
- Germline p53 mutations are associated with a subset of familial ovarian cancers, implicating p53 in hereditary EOC.
- Lack of HER-2/neu overexpression may contribute to the distinct clinical behavior of familial ovarian cancer.